Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
Malignant hydrothorax and ascitic fluid in advanced breast cancer often arise from metastasis to the lungs, pleura, or liver. Patients with this condition experience rapid disease progression and multidrug resistance, facing limited treatment options. Clinical guidelines offer various therapies based on molecular subty
| Condition(s) | Breast Cancer Metastatic, Hydrothorax, Ascites, Organoids, Drug Evaluation |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Malignant hydrothorax and ascitic fluid in advanced breast cancer often arise from metastasis to the lungs, pleura, or liver. Patients with this condition experience rapid disease progression and multidrug resistance, facing limited treatment options. Clinical guidelines offer various therapies based on molecular subtypes; however, their effectiveness can be hindered by prior treatments, patient health, and tumor evolution. Current evaluations of treatment efficacy typically take two cycles, delaying the recognition of ineffective therapies and resulting in unnecessary side effects and costs. Organoid models present a promising solution, accurately replicating tumor structure and cellular diversity compared to traditional methods. These patient-derived models facilitate improved drug sensi |
| Who can participate | Inclusion Criteria: 1. Signed informed consent form and willingness to participate in the clinical study. 2. patients aged between 18 and 70 years old. 3. Confirmed metastatic breast cancer patients with hydrothorax and ascite fluid, which was verified to contain tumor cells by lab. 4. ECOG performance status score of 0-1. 5. No significant abnormalities in liver and kidney function (BIL \<1.5-fold upper limit of normal (ULN)；ALT\<2.5×ULN; AST\<2.5×ULN；Crea≤1×ULN). Exclusion Criteria: 1.Patients not suitable for chemotherapy and target therapy |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Locations | Hangzhou, Zhejiang, China; Hangzhou, Zhejiang, China; Hangzhou, Zhejiang, China |
| Start date | 2024-11-09 |
| NCT ID | NCT06658080 |
| Official listing | https://clinicaltrials.gov/study/NCT06658080 |